Trial Outcomes & Findings for Reducing Dynamic Hyperinflation Through Breathing Retraining (NCT NCT01009099)
NCT ID: NCT01009099
Last Updated: 2015-02-18
Results Overview
The primary outcome measure is a comparison of time walked on the constant workrate treadmill best at 12 weeks.
COMPLETED
PHASE2/PHASE3
119 participants
baseline and 12 weeks
2015-02-18
Participant Flow
Patients were recruited from a midwestern VA hospital and were also referred from other patients and private practices.
204 patients signed informed consents and were screened for participation in the study. 85 patients did not meet eligibility criteria for the following reasons: PFT results did not meet study criteria, claudication, cardiac issues, non-compliance, changed their mind, and active substance use. 119 patients were enrolled in the protocol.
Participant milestones
| Measure |
Exercise Training With Breathing Retraining
treadmill exercise training plus breathing retraining using a metranome
|
Exercise Training
treadmill exercise training
|
|---|---|---|
|
Overall Study
STARTED
|
58
|
61
|
|
Overall Study
COMPLETED
|
53
|
57
|
|
Overall Study
NOT COMPLETED
|
5
|
4
|
Reasons for withdrawal
| Measure |
Exercise Training With Breathing Retraining
treadmill exercise training plus breathing retraining using a metranome
|
Exercise Training
treadmill exercise training
|
|---|---|---|
|
Overall Study
Lost to Follow-up
|
1
|
0
|
|
Overall Study
Physician Decision
|
3
|
2
|
|
Overall Study
Withdrawal by Subject
|
1
|
1
|
|
Overall Study
Death
|
0
|
1
|
Baseline Characteristics
Reducing Dynamic Hyperinflation Through Breathing Retraining
Baseline characteristics by cohort
| Measure |
Arm 1
n=58 Participants
exercise training with breathing retraining
breathing retraining: breathing retraining using a metronome
exercise training: treadmill exercise training
|
Arm 2
n=61 Participants
exercise training
exercise training: treadmill exercise training
|
Total
n=119 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Peak oxygen uptake
|
15.7 VO2 mL/kg/min
STANDARD_DEVIATION 3.9 • n=5 Participants
|
16.6 VO2 mL/kg/min
STANDARD_DEVIATION 3.3 • n=7 Participants
|
16.1 VO2 mL/kg/min
STANDARD_DEVIATION 3.6 • n=5 Participants
|
|
Time on treadmill constant workrate test
|
6.8 minutes walked
STANDARD_DEVIATION 2.5 • n=5 Participants
|
6.9 minutes walked
STANDARD_DEVIATION 2.3 • n=7 Participants
|
6.9 minutes walked
STANDARD_DEVIATION 2.4 • n=5 Participants
|
|
RV/TLC
|
171.3 percent predicted
STANDARD_DEVIATION 30.3 • n=5 Participants
|
168.2 percent predicted
STANDARD_DEVIATION 26.6 • n=7 Participants
|
169.7 percent predicted
STANDARD_DEVIATION 28.4 • n=5 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Black or African American
|
16 Participants
n=5 Participants
|
14 Participants
n=7 Participants
|
30 Participants
n=5 Participants
|
|
Race (NIH/OMB)
White
|
42 Participants
n=5 Participants
|
47 Participants
n=7 Participants
|
89 Participants
n=5 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Region of Enrollment
United States
|
58 participants
n=5 Participants
|
61 participants
n=7 Participants
|
119 participants
n=5 Participants
|
|
Body Mass Index
|
30.0 kg/m2
STANDARD_DEVIATION 6.7 • n=5 Participants
|
29.3 kg/m2
STANDARD_DEVIATION 6.2 • n=7 Participants
|
29.7 kg/m2
STANDARD_DEVIATION 6.5 • n=5 Participants
|
|
FEV1
|
43.7 percent predicted
STANDARD_DEVIATION 14.9 • n=5 Participants
|
44.0 percent predicted
STANDARD_DEVIATION 13.9 • n=7 Participants
|
43.8 percent predicted
STANDARD_DEVIATION 14.3 • n=5 Participants
|
|
FEV1/FVC
|
46.6 percent
STANDARD_DEVIATION 13.3 • n=5 Participants
|
45.1 percent
STANDARD_DEVIATION 12.1 • n=7 Participants
|
45.8 percent
STANDARD_DEVIATION 12.7 • n=5 Participants
|
|
Age, Continuous
|
65.8 years
STANDARD_DEVIATION 7.9 • n=5 Participants
|
66.3 years
STANDARD_DEVIATION 8.1 • n=7 Participants
|
66.0 years
STANDARD_DEVIATION 8.0 • n=5 Participants
|
|
Sex: Female, Male
Female
|
4 Participants
n=5 Participants
|
2 Participants
n=7 Participants
|
6 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
54 Participants
n=5 Participants
|
59 Participants
n=7 Participants
|
113 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
1 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
57 Participants
n=5 Participants
|
61 Participants
n=7 Participants
|
118 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
PRIMARY outcome
Timeframe: baseline and 12 weeksPopulation: Patients who completed 12 weeks of exercise training were analyzed. There was one patient in each group that did not complete the treadmill test at 12 weeks although they completed other secondary outcome measures. Although they did not complete this measure, they remained in the study and were not counted as a drop.
The primary outcome measure is a comparison of time walked on the constant workrate treadmill best at 12 weeks.
Outcome measures
| Measure |
Exercise Training With Breathing Retraining
n=52 Participants
treadmill exercise training plus breathing retraining using a metranome
|
Exercise Training
n=56 Participants
treadmill exercise training
|
|---|---|---|
|
Exercise Duration (Time Walked on the Constant Workrate Treadmill Test)
|
15.2 minutes
Standard Deviation 14.8
|
17.6 minutes
Standard Deviation 14.1
|
Adverse Events
Exercise Training With Breathing Retraining
Exercise Training
Serious adverse events
| Measure |
Exercise Training With Breathing Retraining
n=58 participants at risk
treadmill exercise training plus breathing retraining using a metranome
|
Exercise Training
n=61 participants at risk
treadmill exercise training
|
|---|---|---|
|
Nervous system disorders
ischemic cerebrovascular
|
0.00%
0/58 • Adverse events were collected over 6 months (baseline through end of study or 6 months).
|
3.3%
2/61 • Adverse events were collected over 6 months (baseline through end of study or 6 months).
|
|
Musculoskeletal and connective tissue disorders
fracture
|
1.7%
1/58 • Adverse events were collected over 6 months (baseline through end of study or 6 months).
|
0.00%
0/61 • Adverse events were collected over 6 months (baseline through end of study or 6 months).
|
|
Musculoskeletal and connective tissue disorders
pain
|
0.00%
0/58 • Adverse events were collected over 6 months (baseline through end of study or 6 months).
|
1.6%
1/61 • Adverse events were collected over 6 months (baseline through end of study or 6 months).
|
|
Vascular disorders
arterial injury-extremity lower
|
0.00%
0/58 • Adverse events were collected over 6 months (baseline through end of study or 6 months).
|
1.6%
1/61 • Adverse events were collected over 6 months (baseline through end of study or 6 months).
|
|
Infections and infestations
infection peripheral nerve
|
0.00%
0/58 • Adverse events were collected over 6 months (baseline through end of study or 6 months).
|
1.6%
1/61 • Adverse events were collected over 6 months (baseline through end of study or 6 months).
|
Other adverse events
| Measure |
Exercise Training With Breathing Retraining
n=58 participants at risk
treadmill exercise training plus breathing retraining using a metranome
|
Exercise Training
n=61 participants at risk
treadmill exercise training
|
|---|---|---|
|
Respiratory, thoracic and mediastinal disorders
COPD Exacerbation
|
3.4%
2/58 • Number of events 2 • Adverse events were collected over 6 months (baseline through end of study or 6 months).
|
8.2%
5/61 • Number of events 6 • Adverse events were collected over 6 months (baseline through end of study or 6 months).
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place